BAY-1895344 | ATR inhibitor | Probechem Biochemicals

Chemical Structure : BAY-1895344

CAS No.: 1876467-74-1

BAY-1895344 (Elimusertib, BAY1895344)

Catalog No.: PC-60277Not For Human Use, Lab Use Only.

BAY 1895344 (BAY1895344, Elimusertib) is a novel potent, highly selective ATR kinase inhibitor with IC50 of 7.0 nM.

Packing	Price	Stock
5 mg	$88	In stock
10 mg	$128	In stock
25 mg	$198	In stock
50 mg	$328	In stock
100 mg		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

BAY 1895344 (BAY1895344, Elimusertib) is a novel potent, highly selective ATR kinase inhibitor with IC50 of 7.0 nM.

BAY 1895344 (Elimusertib) demonstrated high selectivity in an in-house kinase selectivity panel (with exception mTOR IC50=35 nM) and KINOMEscan profiling.

BAY 1895344 inhibited hydroxyurea-induced ATR-dependent H2AX phosphorylation with IC50 of 36 nM in HT-29 cells.

BAY 1895344 inhibits proliferation in a broad spectrum of human cancer cell lines ( Lymphoma cells IC50=9-32 nM).

BAY 1895344 shows strong antitumor efficacy as monotherapy in CDX models, as well as synergistic activity in combination with chemotherapy or EBRT.

Physicochemical Properties

M.Wt	375.436
Formula	C20H21N7O
Appearance	Solid
CAS No.
Storage	Solide Powder -20 °C 12 Months; 4°C 6 Months	In Solvent -80 °C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	(R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine

References

1. Lücking U, et al. J Med Chem. 2020 Jul 9;63(13):7293-7325.

2. Wengner AM, et al. Mol Cancer Ther. 2020 Jan;19(1):26-38.

3. Yap TA, et al. Cancer Discov. 2021 Jan;11(1):80-91.

BAY-1895344 (Elimusertib, BAY1895344)

Biological Activity

Physicochemical Properties

References

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

Get Quote

* Indicates a Required FieldYour information is safe with us.